1. Johnson M, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase—deficient patient after treatment with topical 5—fluorouracil. Clin Cancer Res. 1999;5(8):2006–11.
2. Van Kuilenburg AB, Baars JW, Meinsma R, van Gennip AH. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dyhydropyrimidine dehydrogenase gene. Ann Oncol. 2003;14(2):341–2.
3. Papnastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014;34(4):1531–5.
4. Tutrone W, Saini R, Selin Caglar, et al. Topical therapy for actinic keratoses, I: 5—fluorouracil and imiquinod. Cutis. 2003;71(5):365–70.
5. Johnson M, Diasio R. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul. 2001;41:151–7.